Biologics: Shifting Patent Estates and the Legal Challenges Keeping You Up at Night

In 2010, Congress approved the Biologics Price Competition and Innovation Act (BPCIA), creating an abbreviated approval pathway for biosimilars. While several have been approved, biosimilars have been met with increasingly complex and fortified patent estates—escalating the number of legal challenges launched against them.

Join us as our panelists lead a three-part in-depth discussion of biologics:

1. Analysis of patent lifecycle management strategies employed by branded biologics
2. Examination of the Inter Partes Review challenges mounted against blockbuster biologics
3. Discussion of the BPCIA "patent dance" and the implications of the US Supreme Court decision in Sandoz v. Amgen

Questions?
To register or for more information, please contact Tara Graves.